Dr. Tomlinson presents at 3rd Annual Great Lakes Biorepository Network Scientific Meeting

tomlinson-crop-2016The 3rd Annual Great Lakes Biorepository Network (GLBRN) Scientific Meeting was held on October 28, 2016 at the University of Michigan in Ann Arbor. Center Director and Professor Dr. Tom Tomlinson spoke on “Preferences for Biobank Consent Policy are Sensitive to Concerns about Future Research Uses.”

The current research ethics framework gauges the level of ethical protections to the degree of risk to the participant. The lower the risk, the less stringent the requirements for informed consent; when the risk is virtually zero, as with the research uses of de-identified biospecimens and related clinical and demographic data, it is no longer research on a human “subject.”

This framework forgets why people donate their specimens and data to biobanks. They are not merely concerned with what later research will do to or for them. They are hoping their donation may do some good; and correlatively, assuming that it will do no wrong, in ways they would find morally concerning:

  • Some research might threaten a donor’s world view –such as research to better understand human evolution and history.
  • Some donors might be concerned by research that might lead to the stigmatization of others –such as research that looks at genes associated with violence.
  • Or some research may be contrary to the moral, cultural, or political values of the donor – such as research related to abortion or research leading to large commercial profits.

To emphasize the contrasts with the conventional framework, Dr. Tomlinson and his colleagues call these people’s non-welfare interests in later research uses of their donations.

In the talk Dr. Tomlinson presented evidence that such concerns affect people’s preferences among various biobank consent policies, drawn from both a national survey that his research team conducted in 2014 and a series of democratic deliberations held in 2015. The evidence shows that the more people are aware of the range of possible research uses of biobank donations that might be of concern to them or others, the more negative their attitudes are toward blanket consent. In this consent, a donor gives permission up front to any future uses that the biobank would allow, without any further consent or information provided. This is the most common form of biobank consent, but their research shows that a bare majority finds it “acceptable,” and a sizeable minority (38%) think it’s the “worst” option among those presented. Interestingly, the team found similar attitudes expressed toward specific, study-by-study consent, the option that gives each donor the most control over later research uses.

For more analysis of the national survey, see: De Vries RG, Tomlinson T, Kim HM, Krenz C, Haggerty D, Ryan KA, Kim SY. Understanding the Public’s Reservations about Broad Consent and Study-By-Study Consent for Donations to a Biobank: Results of a National Survey. PLoS One. 2016 Jul 14;11(7).

Dr. Tomlinson is an Executive Board Member of the Great Lakes Biorepository Network and Incoming President for 2017.

Understanding the Public’s Reservations about Broad Consent and Study-By-Study Consent for Donations to a Biobank: Results of a National Survey

PLOS ONE logoA new research article from Dr. Tomlinson and his research team was published on July 14, 2016 in the open-access peer-reviewed journal PLoS ONE. The article, “Understanding the Public’s Reservations about Broad Consent and Study-By-Study Consent for Donations to a Biobank: Results of a National Survey,” is authored by Raymond Gene De Vries, Tom Tomlinson, Hyungjin Myra Kim, Chris Krenz, Diana Haggerty, Kerry A. Ryan, and Scott Y. H. Kim. The research is part of the NIH-funded project “Public Preferences for Addressing Donors’ Moral Concerns about Biobank Research.”

Abstract: Researchers and policymakers do not agree about the most appropriate way to get consent for the use of donations to a biobank. The most commonly used method is blanket—or broad—consent where donors allow their donation to be used for any future research approved by the biobank. This approach does not account for the fact that some donors may have moral concerns about the uses of their biospecimens. This problem can be avoided using “real-time”—or study-by-study—consent, but this policy places a significant burden on biobanks. In order to better understand the public’s preferences regarding biobank consent policy, we surveyed a sample that was representative of the population of the United States. Respondents were presented with 5 biobank consent policies and were asked to indicate which policies were acceptable/unacceptable and to identify the best/worst policies. They were also given 7 research scenarios that could create moral concern (e.g. research intending to make abortions safer and more effective) and asked how likely they would be to provide broad consent knowing that their donation might be used in that research. Substantial minorities found both broad and study-by-study consent to be unacceptable and identified those two options as the worst policies. Furthermore, while the type of moral concern (e.g., regarding abortion, the commercial use of donations, or stem cell research) had no effect on policy preferences, an increase in the number of research scenarios generating moral concerns was related to an increased likelihood of finding broad consent to be the worst policy. The rejection of these ethically problematic and costly extremes is good news for biobanks. The challenge now is to design a policy that combines consent with access to information in a way that assures potential donors that their interests and moral concerns are being respected.

“Understanding the Public’s Reservations about Broad Consent and Study-By-Study Consent for Donations to a Biobank: Results of a National Survey” is available to read in full on the PLoS ONE website.

HIV prevention: benefits, barriers, and ethical concerns

bbag-icon-decEthical Implications of HIV Pre-Exposure Prophylaxis (PrEP) for African American Women and Adolescent Girls

Event Flyer

Pre Exposure Prophylaxis (PrEP) is a new HIV prevention strategy approved by the Food and Drug Administration for use by uninfected, high-risk adult populations. PrEP’s potential as an HIV preventive strategy/biomedical method for adolescents is unknown. The presentation will present preliminary results from a study that examined benefits, barriers, and ethical concerns associated with Pre-exposure Prophylaxis (PrEP) utilization and clinical trial participation among African American adolescent girls. Study findings have the potential to generate evidence-based data to inform HIV research ethics practices and increase just and fair access to HIV scientific advances.

feb-17-bbagJoin us for Faith Fletcher’s lecture on Wednesday, February 17, 2016 from noon till 1 pm in person or online.

Faith E. Fletcher is an Assistant Professor in the Division of Community Health Sciences at the University of Illinois at Chicago (UIC). Prior to joining UIC faculty in 2013, Dr. Fletcher completed a National Cancer Institute R25T- funded postdoctoral fellowship in the Department of Behavioral Science at the University of Texas MD Anderson Cancer Center. The ultimate goal of her research program is to address HIV-related health inequities by understanding barriers that prevent African American women and adolescent girls from accessing innovative HIV preventive methods and treatment. Recent awards include joint funding through the Developmental Center for AIDS Research and Center for Clinical and Translational Science; Kaiser Permanente Burch Minority Leadership Fellowship; Building Interdisciplinary Careers in Women’s Health Research (BIRCWH K12) Fellowship; Visiting Professor in Minority Health through Northwestern Feinberg School of Medicine’s Program in Public Health; and an HIV Research Ethics Training Institute (RETI) Fellowship through Fordham University’s Center for Ethics Education. Dr. Fletcher received her foundation in bioethics and social justice through Tuskegee University’s National Center for Bioethics in Research and Health Care and Michigan State University’s Interdisciplinary Program in Bioethics, Humanities and Society. She completed her PhD in Health Behavior and Promotion from the University of South Carolina Arnold School of Public Health in 2011.

In person: This lecture will take place in C102 East Fee Hall on MSU’s East Lansing campus. Feel free to bring your lunch! Beverages and light snacks will be provided.

Online: Here are some instructions for your first time joining the webinar, or if you have attended or viewed them before, go to the meeting!

Can’t make it? All webinars are recorded! View our archive of recorded lectures.

Do People Care What’s Done with Their Biobanked Samples?

tomlinsonCenter Director Dr. Tom Tomlinson has a new article in the July-August issue of IRB: Ethics & Human Research. 

Abstract: When donating leftover biological samples to a biobank for use in medical research, people generally are asked to give a broad consent. This allows their samples and associated medical information to be later used without any further consent. Although risks to donors are virtually eliminated by deidentification of their samples, some donors may have concerns about the moral dimensions of research using their biological samples. We used an Internet survey of Michigan residents (N = 683) to determine the effects that information about future possible research uses has on people’s willingness to donate their biological samples under a broad consent. The presentation of research projects that might raise moral concerns for some individuals reduced the number of respondents willing to give a broad consent and reduced confidence in their decision among those still willing to donate. Even so, the great majority (> 85%) remained willing to donate. We discuss the implications of these findings for the consent and information-sharing policies of biobanks.

Read “Do People Care What’s Done with Their Biobanked Samples?” by Tom Tomlinson, Stan A. Kaplowitz, and Meghan Faulkner via thehastingscenter.org.
MSU Library access may be required to view this publication.

Allan Loup of the University of Michigan Medical School to discuss the obligations of researchers at January webinar

bbag-iconAre Researchers Ever Obligated to Provide Individual Research Findings to Non-participant Third Parties?

Event flyer: Loup Flyer

A consensus is emerging that, in some circumstances, researchers have obligations to return individual research results to research participants. Recent methodological advances in genetics research suggest that researchers will increasingly uncover potentially pathogenic, actionable information relevant to individuals, such as family members of participants, who never involved themselves in research. Are investigators ever obligated to provide findings to these non-participant third parties? What could explain such obligations?

jan15Join us for Allan Loup’s lecture on Wednesday, January 15, 2014 from noon till 1 pm in person or online:

In person: The lecture will take place in C102 East Fee Hall on MSU’s East Lansing campus. Feel free to bring your lunch! Beverages and light snacks will be provided.

Online: Here are some instructions for your first time joining the webinar, or if you have attended or viewed them before, go to the meeting!

Allan Loup, JD, is a Regulatory Affairs Specialist at the University of Michigan Medical School. Loup graduated from the University of Michigan, received his law degree from Washington University in St. Louis, and trained in medical ethics at the MacLean Center for Clinical Medical Ethics at the University of Chicago. His current work addresses ethical and regulatory issues in the administration of research biorepositories.